Nemaura Pharma, based on Loughborough University Science and Enterprise Park, has developed an efficient and cost-effective pain-relief system for sufferers of acute arthritic-related pain.

The company has developed two new gels which, in laboratory, trials achieve up to three-times faster drug penetration rate and faster onset of action.

They also provide up to 48 hours sustained impact from a single application when administered through the skin using Nemaura’s proprietary delivery system Memspatch®.

The versatile proprietary gel formulations and delivery technologies can be used with a large number of established medications to provide either a rapid or controlled slow delivery of drug formulations.

Nemaura’s focus on developing a more efficient and cost-effective pain-relieving system has the potential to significantly contribute to the fast-growing non-steroidal anti-inflammatory drug (NSAID) global market valued, in 2015, at almost £9 billion per year.

Commenting on the study results, Nemaura CEO Dr Faz Chowdhury said: “Our goal is to improve the life experience of anyone affected by pain.

“We are excited by our progress, as these results bring a new product closer to market. In the past six months we have grown our team of device technologists, chemists, and scientists to 35, and plan for further expansion in 2018 on the back of these promising results.”

In 2016, Nemaura received the Frost & Sullivan Global recognition of its advanced capability in skin drug delivery.

With patents secured or pending in multiple countries across numerous patent families, Nemaura aims to be one of the leading pharmaceutical technologists in this fast-growing market, which is expected to be worth £33 billion by 2018.

To find out more about Nemaura Pharma, please click here.

Latest Opportunities

Study brief: The effects of a recovery gel on endurance cycling performance in the heat

The popularity of endurance sports like cycling and running has grown significantly over the past…

UKRI unveils new £9 million proof-of-concept fund

The UKRI Proof of Concept funding opportunity aims to support and accelerate the development of…

Peer advice on “demand forecasting strategies”

An established Midlands-based health manufacturer is keen to hear from others about their demand forecasting…

Latest News

Illuminating biology: Advanced imaging and computational techniques transforming medical research at the University of Warwick

Advances in imaging and computational techniques are enabling researchers to discover more than ever before…

From firefighting to future-proofing: Why predictive compliance is key in medical device software

By Medilink Midlands Member Coauthor by Hindsight In today’s fast-paced and highly regulated world of…

IMed Consultancy new whitepaper reveals how to transform gruelling PMS procedures into commercial benefit

IMed Consultancy’s new free whitepaper, “PMS from pain to potential: more than just ticking a…